← Back to Drug List

DUPILUMAB INJ,SOLN

Clinical Criteria Summary

Document 55

Exclusion Criteria

  • Concurrent use of live (attenuated) vaccines or treatment with live (attenuated) vaccines within the previous 4 weeks.
  • Concurrent use with targeted immunomodulators unless potential risk-benefits favor use.
  • Untreated parasitic (helminth) infection.
  • Existing diagnosis of cutaneous T-cell lymphoma (CTCL), mycosis fungoides, or Sézary syndrome unless potential benefits outweigh risks (relative contraindication).

Inclusion Criteria (New Starts)

  • Diagnosis of chronic atopic dermatitis made or confirmed by a VA / VA Community Care dermatologist.
  • Prescribed by a VA / VA Community Care dermatologist, allergist, or immunologist, or other designated expert in the management of atopic dermatitis in consultation with a VA / VA Community Care dermatologist, allergist, or immunologist.
  • Offered all age-appropriate vaccinations prior to initiating therapy.
  • Assessment of moderate to severe atopic dermatitis in the last 2 weeks as determined by either a gestalt assessment of “moderate” or “severe” OR Eczema Area and Severity Index (EASI) ≥ 16 (scale 0–72).
  • Refractory to ≥ 2 classes of topical therapies for atopic dermatitis (e.g., corticosteroids, calcineurin inhibitors, PDE4 inhibitors, JAK inhibitors) for ≥ 4 weeks total unless the therapy is medically inadvisable or not tolerated.

Additional Inclusion Criteria

  • For females who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy.
  • For females who are breastfeeding/providing breastmilk to an infant: Counseling provided on potential risks vs benefits of treatment.

Sequencing & Therapy Considerations

  • If patient weighs < 100 kg, consider tralokinumab prior to dupilumab.
  • First-line therapies include dupilumab, tralokinumab-ldrm, lebrikizumab-lbkz, or nemolizumab-ilto.
  • Second-line therapies include abrocitinib or upadacitinib.
  • Consider offering methotrexate, azathioprine, mycophenolate mofetil in the context of shared decision-making (prior trials not required), with use conditional on factors such as lower certainty of risk-benefits, slower onset, feasibility of adhering to follow-ups, comorbidities, and patient values/preferences.

Document 216

Exclusion Criteria

  • History of hypersensitivity to dupilumab or any of its excipients
  • Concurrent use of live (attenuated) vaccines or treatment with live (attenuated) vaccines within the previous 12 weeks
  • Currently treated with omalizumab or another biologic agent
  • Untreated parasitic (helminth) infection

Inclusion Criteria

  • Care provided by a VA / VA Community Care (Allergy, Immunology or Otolaryngology [ear, nose and throat] specialist) or locally designated expert in managing CRSwNP
  • Diagnosis of CRSwNP is confirmed
  • Symptoms of CRSwNP are uncontrolled and persistent despite use of ALL of the following:
  • Daily use and adherence to topical corticosteroid (CS) nasal spray (e.g., fluticasone)
  • Daily use and adherence to nasal saline spray/irrigations
  • Trial of nasal CS irrigation (e.g., 4-6 weeks budesonide added to topical CS and nasal saline sprays/irrigations)
  • Short-term course of systemic CS within the past 2 years (unless contraindicated)
  • Sinonasal surgery has been performed (e.g., surgical/endoscopic intervention(s) to remove nasal polyps/tissue, unless patient is not a surgical candidate or surgery is not indicated) and continued adherence to maximal medical therapies after surgery has been confirmed with the patient

Dosing & Administration

  • FDA-approved dosing schedule for CRSwNP is every 2 weeks
  • Clinical trials (SINUS-24 and SINUS-52) showed no statistically different outcomes between administering dupilumab every 2 weeks vs. every 4 weeks

Safety & Clinical Management

  • Hypersensitivity reactions reported in <1% of patients in clinical trials (e.g., generalized urticaria, rash, erythema nodosum and serum sickness or serum sickness-like events)
  • If a hypersensitivity reaction occurs, appropriate therapy should be instituted and dupilumab discontinued

Document 377

Exclusion Criteria

  • Concurrent use of live (attenuated) vaccines or treatment with live (attenuated) vaccines within the previous 12 weeks
  • Untreated parasitic (helminth) infection

Inclusion Criteria

  • Diagnosis of eosinophilic esophagitis (EoE) including histologic evidence of eosinophilic inflammation (≥ 15 eosinophils / high power field) made or confirmed by a VA / VA Community Care gastroenterologist
  • Prescribed by a VA / VA Community Care gastroenterologist OR an immunologist, allergist, or other designated expert in the management of EoE in consultation with a VA / VA Community Care gastroenterologist
  • Tried a swallowed topical glucocorticoid (e.g., swallowed aerosolized fluticasone or commercially available budesonide oral suspension) for at least 8 to 12 weeks, unless medically inadvisable, and had an inadequate response or intolerance

Additional Inclusion Criteria

  • For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy

Document 378

Indication

  • Treatment of adults with eosinophilic esophagitis (EoE)

Patient Selection & Clinical Criteria

  • Histologic confirmation of eosinophilic inflammation (≥ 15 intraepithelial eosinophils per high-power field [eos/hpf])
  • Significant symptoms: average ≥ 2 episodes of dysphagia with intake of solids per week in the previous 4 weeks
  • Inadequate response or intolerance to prior trials of proton pump inhibitors (PPIs) administered twice daily for ≥ 8 weeks
  • Prior trials of swallowed topical glucocorticoids (STGs) (≥ 8 weeks) and dietary therapy are considered, though a prior trial of systemic glucocorticoids is not required
  • Patients should be strongly motivated/adherent with access to dietitian support if dietary therapy is utilized

Dosing & Administration

  • 300 mg subcutaneous (SC) every week (QW)
  • Dose is higher and more frequent than for other approved indications

Place in Therapy

  • Third-line pharmacologic treatment alternative for EoE

Safety Considerations & Monitoring

  • Adverse events observed include injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections (≥ 2% incidence)
  • Conjunctivitis and keratitis were reported at 0% in the dupilumab group
  • Long-term safety and risk of loss of efficacy require further assessment beyond short-term trials
  • Symptomatic remission does not reliably correlate with histologic remission; both histologic end points (reduction in eosinophilic inflammation) and clinical signs/symptoms are important outcome measures

Un-Evaluated Populations & Precautions

  • Safety and efficacy have not been evaluated in patients in complete symptomatic remission
  • Safety and efficacy have not been evaluated in patients with prior esophageal surgery
  • Safety and efficacy have not been evaluated in patients with an esophageal stricture unable to be passed with a 9- to 10-mm standard diagnostic endoscope
  • Safety and efficacy have not been evaluated in patients with a critical esophageal stricture requiring dilation
  • Use in the above un-evaluated populations should be adjudicated on a case-by-case basis

Document 517

Indication & Patient Population

  • • Treatment of adult patients with prurigo nodularis (PN)
  • • Patients with a documented diagnosis of PN and ≥ 20 nodules
  • • Patients presenting with severe itch despite use of topical therapies

Treatment Prerequisites & Step Therapy Requirements

  • • Inadequate response (after ≥ 2 weeks per therapy) or intolerance to one of the following:
  • – Two topical therapies (e.g., medium, high, or super-high corticosteroids [where different strengths count as different therapies], calcipotriene, or calcineurin inhibitor)
  • – One topical therapy and an intralesional corticosteroid
  • • Applicable unless these prior therapies are medically inadvisable

Dosing & Administration

  • • Initial: 600 mg (two 300-mg injections) subcutaneously (SC)
  • • Maintenance: 300 mg SC every 2 weeks
  • • Formulation: Single-dose prefilled syringe or single-dose prefilled pen: 300 mg/2 mL

Safety & Clinical Considerations

  • • Boxed warnings, contraindications, and other warnings/precautions apply as for previous indications
  • • Common adverse events (≥ 2% of dupilumab group and greater than placebo): Nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, diarrhea
  • • Patients with atopic dermatitis-related PN require more weeks of treatment to achieve response compared to non-atopic dermatitis-related PN patients
  • • Complete remission is rarely observed before 4 months of therapy; 2 months of therapy are required before itch is relieved

Document 707

Provider & Care Setting

  • Provider must be a VA or VA Community Care pulmonologist or designated expert.

Disease Severity & Phenotype

  • Moderate to severe COPD (post-bronchodilator FEV 30-70% predicted and FEV /FVC <0.7, confirmed by pulmonary function testing).
  • Signs or symptoms of chronic bronchitis (chronic productive cough) for at least 3 months during the past year.

Exacerbation History & Symptom Control

  • At least 2 moderate COPD exacerbations (requiring systemic steroids and/or antibiotics) or at least 1 severe COPD exacerbation (requiring hospitalization) in the previous 12 months.
  • Inadequate symptom control (e.g., mMRC dyspnea scale score > 2.) or impaired health status (e.g., CAT score > 15).

Biomarkers

  • Blood eosinophils ≥300 cells/µL obtained prior to treatment (e.g., within the prior 3 months).

Prior Therapy & Treatment Trials

  • Receiving concurrent triple inhaled therapy with a long-acting beta-agonist (LABA) AND a long-acting anticholinergic (LAMA) AND an inhaled corticosteroid (unless inhaled corticosteroid is contraindicated) for at least 3 months.
  • Unable to tolerate or had an inadequate response to a (6-month) trial of roflumilast and to a (6-month) trial of azithromycin, unless not clinically appropriate for either agent.

Adherence & Technique

  • Adherent to COPD medications as evidenced by a review of prescription refill history.
  • Demonstrated correct inhaler technique (documented in chart).

Safety & Contraindications (Exclusion Criteria)

  • Untreated acute bronchospasm or an acute exacerbation of chronic obstructive pulmonary disease (COPD).
  • Concurrent use of live (attenuated) vaccines or treatment with live (attenuated) vaccines within the previous 4 weeks.
  • Untreated parasitic (helminth) infection (treat infection prior to initiating dupilumab).
  • Concurrent use with therapeutic biologics unless potential benefit-risk favors use.

Special Populations & Additional Considerations

  • For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy.
  • Patient is non-smoking or, if not, enrolled in a quit smoking program or on medications to assist with smoking cessation (current smokers may be considered if unable or refuse to quit).
  • Address modifiable environmental triggers for Type 2 inflammation, if not already done.

Document 800

Indication & Patient Population

  • Adults with bullous pemphigoid (BP)
  • Moderate to severe BP or patients requiring systemic therapy
  • Refractory/resistant to combined topical corticosteroids (TCS) and oral corticosteroids (OCS)
  • Histopathologically, immunopathologically, and serologically confirmed diagnosis
  • Bullous Pemphigoid Disease Area Index (BPDAI) activity score ≥ 24
  • Weekly average Peak Pruritus NRS (PP-NRS) score ≥ 4

Dosing & Administration

  • 600 mg SC once, then 300 mg SC every 2 weeks
  • Use in combination with a tapering course of OCS
  • Once disease control occurs, gradually taper OCS and continue dupilumab as monotherapy
  • Add corticosteroids if medically advisable in case of relapse

Pretreatment & Monitoring

  • No pretreatment procedures required
  • No laboratory monitoring required
  • Monitor for keratoconjunctivitis

Safety Considerations

  • Nonimmunosuppressant (advantageous for older patients with comorbidities)
  • Top 5 adverse events: arthralgia, conjunctivitis, blurred vision, herpes viral infections, keratitis

Place in Therapy

  • FDA-approved for BP
  • Potential first-line (1L) treatment in combination with a tapering course of OCS for moderate to severe BP or when systemic therapy is indicated
  • Considered for BP resistant to combined TCS and OCS; once disease controlled, OCS may be tapered before continuing dupilumab as monotherapy

Document 801

Indication & Patient Population

  • Adults and pediatric patients > 12 years with chronic spontaneous urticaria (CSU)
  • Patients who remain symptomatic despite treatment with H1 antihistamines (up to 4x usual daily dose)
  • Not indicated for patients with inducible urticaria, diseases other than urticaria associated with hives or angioedema, active atopic dermatitis, or other skin conditions that could interfere with outcome assessments

Dosing & Administration

  • Initial dose: 600 mg
  • Maintenance dose: 300 mg every 2 weeks
  • Continue H1 antihistamines; titrate up to 4x usual daily dose as needed
  • Rescue therapy with oral corticosteroids is permitted

Safety, Monitoring & Precautions

  • Contraindicated in patients with known hypersensitivity to dupilumab or any excipients
  • Monitor for and report: Hypersensitivity; conjunctivitis and keratitis (report new eye symptoms); eosinophilic conditions (especially upon reducing oral corticosteroid dose); psoriasis (new onset); arthralgia and psoriatic arthritis (report new onset joint symptoms)
  • Steroid withdrawal precautions: Do not abruptly discontinue oral, topical, or inhaled corticosteroids upon initiation; if needed, gradually decrease steroids
  • Parasitic (Helminth) infections: Treat preexisting infections before initiating treatment
  • Vaccines: Avoid use of live vaccines
  • Pregnancy: Monitor via pregnancy registry; case reports and series have not identified a dupilumab-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
  • Lactation: Weigh benefits of breastfeeding against mother’s clinical need and potential adverse drug events on the breastfed child

Place in Therapy & Step-Down Criteria

  • Recommended as a second-line therapy for patients remaining symptomatic on H1 antihistamines (up to 4x daily dose)
  • Maximum doses of H1 antihistamines should be continued in combination with second-line therapies
  • Not recommended for patients who have not had an adequate response to omalizumab, as they are unlikely to show a greater response to dupilumab
  • Therapy can be stepped down by reducing doses or extending dosing intervals when the urticaria control test (UCT) score equals 16

Document 815

Exclusion Criteria

  • Concurrent use of live (attenuated) vaccines or treatment with live (attenuated) vaccines within the previous 4 weeks
  • Concurrent use with therapeutic biologics unless potential risk-benefits favor use
  • Untreated parasitic (helminth) infection

Inclusion Criteria (Prerequisites)

  • Prescribed by a VA / VA Community Care dermatologist or other designated expert in the management of bullous pemphigoid in consultation with a VA / VA Community Care dermatologist
  • Medications potentially implicated as causing bullous pemphigoid have been discontinued or switched if clinically possible (but this should not necessarily delay initiation of therapy)

Inclusion Criteria (Disease Severity & Treatment History)

  • One of the following must be selected:
  • Documented biopsy and/or serology-confirmed, moderate–severe bullous pemphigoid with moderate–very severe pruritus AND concomitant tapering course of oral corticosteroids unless medically inadvisable
  • Documented mild bullous pemphigoid AND had an inadequate response (after ≥ 4 weeks), intolerance, or medical inadvisability to either high potency topical corticosteroids or oral corticosteroids and either doxycycline/tetracycline or dapsone

Additional Inclusion Criteria (Special Populations)

  • Select if applicable:
  • For females who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy
  • For females who are lactating/providing breastmilk to an infant: Counseling provided on the potential risks vs benefits of treatment

Document 816

Exclusion Criteria

  • Concurrent use of live or live attenuated vaccines (within the past 4 weeks)
  • Untreated parasitic (helminth) infection (treat infection prior to initiating dupilumab)
  • Concurrent use with therapeutic biologics unless potential benefit-risk favors use

Inclusion Criteria

  • Provider is a VA or VA Community Care allergy specialist, dermatologist or designated expert in the management of allergic conditions
  • Diagnosis of severe chronic spontaneous urticaria (e.g., UAS7 >28 and/or UCT <12)
  • Unacceptable symptoms despite a therapeutic trial of 1 non-sedating H antihistamine titrated up to 4 times the usual daily dose
  • Inadequate response to a 3-month trial of omalizumab 300 mg every 4 weeks (minimum of 3 doses), unable to tolerate or not a candidate for omalizumab

Additional Inclusion Criteria

  • For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy; if pregnancy occurs, enrollment in a pregnancy register is recommended

Source Documents